Sugi Predict

Sugi Predict / Compounds / SCHEMBL6863972

SCHEMBL6863972

SCHEMBL6863972

COCCOOC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HINT1 P49773 5/20 0.68
▸ NT5E P21589 1/20 0.68
▸ TGM2 P21980 1/20 0.63
▸ GSK3A P49840 2/20 0.61
▸ RPS6KA3 P51812 2/20 0.61
▸ MAPK14 Q16539 2/20 0.61
▸ IMPDH2 P12268 1/20 0.60
▸ IMPDH1 P20839 1/20 0.60
▸ KRAS P01116 8/20 0.59
▸ PNP P00491 1/20 0.59
▸ FUT5 Q11128 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2533738 0.92 HINT1 (0.69) HINT1NT5ETGM2GSK3ARPS6KA3
SCHEMBL14782966 0.91 HINT1 (0.72) HINT1NT5ETGM2GSK3ARPS6KA3
2'-Beta-Methyl-Guanosine SCHEMBL383785 0.90 HINT1 (0.75) HINT1NT5ETGM2GSK3ARPS6KA3
2'-Beta-Methyl-Guanosine SCHEMBL116165 0.90 HINT1 (0.75) HINT1NT5ETGM2GSK3ARPS6KA3
2'-Beta-Methyl-Guanosine SCHEMBL14178410 0.90 HINT1 (0.75) HINT1NT5ETGM2GSK3ARPS6KA3
2'-Beta-Methyl-Guanosine SCHEMBL11965261 0.90 HINT1 (0.75) HINT1NT5ETGM2GSK3ARPS6KA3
2'-Beta-Methyl-Guanosine SCHEMBL15338533 0.90 HINT1 (0.75) HINT1NT5ETGM2GSK3ARPS6KA3
2'-Beta-Methyl-Guanosine SCHEMBL5972612 0.89 HINT1 (0.73) HINT1NT5ETGM2GSK3ARPS6KA3
SCHEMBL9059278 0.88 HINT1 (0.70) HINT1NT5ETGM2GSK3ARPS6KA3
SCHEMBL16295117 0.87 HINT1 (0.69) HINT1NT5ETGM2GSK3ARPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6111094-A OLIGONUCLEOTIDE WITH AT LEAST ONE 2' MODIFICATION; FOR MODULATION OF HUMAN INTRACELLULAR ADHESION MOLECULE-1; ANTIINFLAMMATORY/ANTICARCINOGENIC/ ANTIMETASTASIS AGENTS; ANTIARTHRITIC AGENTS; TREATMENT OF SKIN DISORDERS ISIS PHARMACEUTICALS INC. (US) 2000-08-29 — — US claimed
WO-2022150369-A1 COMPOUNDS FOR THE TREATMENT OF BATTEN DISEASE EXICURE OPERATING COMPANY (US) 2022-07-14 — — WO disclosed
WO-2022147541-A1 COMPOUNDS FOR MODULATING SCN9A EXPRESSION EXICURE OPERATING COMPANY (US) 2022-07-07 — — WO disclosed
US-6800751-B2 ALKYLATION OF 2'-HYDROXY GROUP OF RIBONUCLEOSIDE PROTECTED WITH INVENTIVE SILYLATING AGENTS IN PRESENCE OF EXCESS OF MILD HINDERED BASE MAY BE CARRIED OUT WITHOUT PROTECTING EXOCYCLIC AMINE AND OXO FUNCTIONALITIES OF NUCLEOBASES ISIS PHARMACEUTICALS, INC. 2004-10-05 — — US disclosed
US-20030225262-A1 Reagent and process for protecting active groups IONIS PHARMACEUTICALS, INC. 2003-12-04 — — US disclosed
WO-2003087053-A2 REAGENT AND PROCESS FOR PROTECTING NUCLEOSIDE ACTIVE GROUPS ISIS PHARMACEUTICALS, INC. (US) 2003-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225262-A1 Reagent and process for protecting active groups TRDMT1, SBDS, DIMT1 HINT1 556/4885NT5E 1193/4885TGM2 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.